Replimune Q2 net loss $43.1M; CERPASS enrollment complete, cash runway extended into 2025

Replimune Group, Inc.

2023-Q2 EPS reported -$1.57

Net loss of $43.1M for Q2 FY2022 (vs $29.4M in Q2 FY2021); R&D expenses $28.8M.
Completed enrollment in CERPASS trial (n=211) of RP1+Libtayo in CSCC; primary data expected H1 2023.
Six-month data from first 75 patients in IGNYTE (RP1+Opdivo anti-PD1 failed melanoma) expected by year-end.
Closed $200M term loan with Hercules Capital; cash and investments $371.8M as of Sep 30, 2022.
Cash runway extended into 2025, covering commercial infrastructure and confirmatory trial costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Replimune Group, Inc. reported financial results for second quarter ended September 30, 2022.

Period: second quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Replimune Group, Inc. issued a news release announcing its financial results for the second quarter ended September 30, 2022 and certain corporate updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-114224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.